Tacrolimus Market Research Report 2026: Key Growth Drivers, Challenges, Future Opportunities, and Regulatory Landscape 2025-2035

The global tacrolimus market is projected to grow from USD 7.3 billion in 2025 to USD 12.7 billion by 2035 at a CAGR of 5.6%, driven by rising organ transplant procedures and increasing autoimmune disease prevalence. Injectable formulations and hospital settings dominate the market, with North America accounting for 40.4% of the market share. Key players are investing in R&D for improved formulations and expanding into emerging markets.

05/25/2026, 5:31 AM • GlobeNewswire

Presbyopia Market to Witness Accelerated Growth at a CAGR of 4.9% During the Forecast Period (2026–2036) Supported by Expanding Treatment Landscape | DelveInsight

The presbyopia market is projected to grow at a CAGR of 4.9% from 2026-2036, driven by an aging global population and expanding treatment options. The market was valued at USD 11 billion in 2025 across seven major markets, with the US accounting for 50% of the market. Multiple emerging therapies and devices are expected to enter the market, including Phentolamine, MicroLine, GLK-302, and CorVision, alongside already-approved treatments like VUITY, QLOSI, VIZZ, and YUVEZZI.

05/11/2026, 1:00 PM • GlobeNewswire

Opus Genetics Announces Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting

Opus Genetics will present three abstracts at the ASCRS Annual Meeting in April 2026, including full results from Phase 3 studies evaluating phentolamine ophthalmic solution for presbyopia and mesopic vision disturbances. The company's partner Viatris is sponsoring an educational symposium on presbyopia management. Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies for inherited retinal diseases and advancing phentolamine as a small-molecule therapy.

04/10/2026, 6:59 AM • GlobeNewswire

Viatris at $14: A Double-Digit FCF Yield Hiding in Plain Sight

Viatris trades at a significant discount despite generating a 13.5% free cash flow yield and $2.2 billion in annual FCF. With a $650 million cost savings program launching in 2026, six regulatory decisions expected, and two Phase 3 assets with blockbuster potential, the stock trades 17% below peer-average EV/EBITDA. The company's differentiated specialty pipeline leverages its unmatched global distribution infrastructure across 40 countries and 165 markets, positioning it for genuine inflection in 2026 with projected first year of top-line growth since formation.

04/02/2026, 3:04 AM • Investing

Systemic Lupus Erythematosus Clinical Trial Pipeline Accelerates as 120+ Pharma Companies Rigorously Developing Drugs for Market Entry | DelveInsight

Over 120 pharmaceutical companies are actively developing 140+ pipeline drugs for systemic lupus erythematosus (SLE), with approximately 30+ drugs in mid-stage development and 85+ in early stages. Key players include Roche, Biogen, Novartis, AbbVie, and Johnson & Johnson, with promising therapies targeting various mechanisms such as B cell inhibitors, JAK inhibitors, and TLR antagonists. Recent regulatory milestones include FDA Fast Track designation for nipocalimab and Breakthrough Therapy Designation for litifilimab.

04/01/2026, 1:00 PM • GlobeNewswire

Viatris Maintains Dividend Policy for 2026 and Announces Quarterly Dividend

Viatris Inc. (NASDAQ: VTRS) announced that its Board of Directors approved a 2026 dividend policy of $0.48 per share and declared a quarterly dividend of $0.12 per share, payable on March 18, 2026. This marks the sixth consecutive year the company has paid a dividend, demonstrating commitment to shareholder returns.

02/26/2026, 6:55 AM • Benzinga

Chronic and Acute Pain Clinical Trial Pipeline Analysis: 150+ Key Companies Shaping the Future of Chronic and Acute Pain Therapeutics | DelveInsight

DelveInsight released a comprehensive analysis of the chronic and acute pain clinical trial pipeline, identifying 150+ active companies developing 200+ pipeline drugs across various clinical stages. The report highlights a shift toward non-opioid, targeted, and multimodal approaches due to growing concerns about opioid dependence. Recent developments include FDA orphan drug designation for Adolore BioTherapeutics' gene therapy, positive Phase IIb results for Dogwood Therapeutics' Halneuron, and Phase III publication of Vertanical's VER-01 for chronic low back pain.

01/28/2026, 1:00 PM • GlobeNewswire

Systemic Lupus Erythematosus Market to Exhibit Growth at a CAGR of 9.4% During the Forecast Period (2025–2034) Owing to Rising Use of Biologics – Approvals of BENLYSTA and SAPHNELO, Plus a Strong Pipeline | DelveInsight

The systemic lupus erythematosus (SLE) market is projected to grow at a CAGR of 9.4% from 2025-2034, driven by rising disease prevalence, increased diagnostic awareness, and a robust pipeline of targeted therapies. The US market was valued at USD 2.8 billion in 2024 with approximately 529K diagnosed cases. Currently, only two FDA-approved therapies exist (BENLYSTA and SAPHNELO), but several promising drugs in mid-to-late stage development are expected to reshape the treatment landscape and address significant unmet medical needs.

01/13/2026, 1:00 PM • GlobeNewswire

These 10 S&P 500 Stocks Are Dirt Cheap This Black Friday

Several S&P 500 stocks are trading at low forward price-to-earnings ratios, suggesting potential undervaluation and possible investment opportunities, with some stocks showing potential upside of up to 50%.

11/28/2025, 10:12 AM • Benzinga

What Occidental Petroleum’s Latest Backer Sees in Oil’s Next Chapter

QSM Asset Management initiated a new $10.31 million position in Occidental Petroleum, acquiring 221,760 shares in Q3 2025, despite the stock's 18.77% decline over the past year.

10/24/2025, 11:36 PM • The Motley Fool

Teva, Viatris On Investor Watch As White House Spares Generic Drugs From Tariffs

The Trump administration will exclude imported generic drugs from potential tariffs, bringing relief to pharmaceutical companies and Indian drugmakers who supply nearly half of U.S. generic prescriptions.

10/09/2025, 9:31 AM • Benzinga

Epinephrine Market to Size to Reach USD 5.74 Billion by 2032 as Demand for Emergency Allergy Treatments Surges – SNS Insider

The global epinephrine market is projected to grow from $2.77 billion in 2024 to $5.74 billion by 2032, driven by increasing cases of severe allergic reactions, technological advancements in auto-injectors, and rising awareness of anaphylaxis risks.

09/01/2025, 9:00 AM • GlobeNewswire

Saudi Arabia Generic Drugs Market Outlook Report 2025-2033 | Government Cost-Cutting, Local Manufacturing, and Public Awareness Fuel Rapid Growth

Saudi Arabia's generic drugs market is projected to grow from $4.05 billion in 2024 to $8.11 billion by 2033, driven by government cost-cutting initiatives, local manufacturing expansion, and increasing healthcare needs.

08/14/2025, 4:09 AM • GlobeNewswire

Theravance Sales Jump 83 Percent

Theravance Biopharma reported Q2 2025 revenue of $26.2 million, driven by YUPELRI sales and a significant one-time gain from TRELEGY royalty asset sale. The company continues to focus on respiratory therapies and is advancing its ampreloxetine clinical program.

08/12/2025, 10:13 PM • The Motley Fool

Postoperative Pain Management Market Poised for Transformation During the Forecast Period (2025–2034) with Rising Non-Opioid Adoption | DelveInsight

The postoperative pain management market is experiencing steady growth, driven by increasing surgical procedures, rising awareness of pain control, and development of non-opioid alternatives. Emerging therapies and innovative drug delivery systems are expected to transform the market landscape by 2034.

08/07/2025, 1:00 PM • GlobeNewswire